bioAffinity Q3 revenue falls to $1.1 million; net loss widens to $5.3 million
bioAffinity Technologies reported third-quarter 2026 revenue of approximately $1.1 million, down from approximately $1.4 million a year earlier, which it attributed to lower reimbursement per CyPath Lung test and a slight decline in cases at its Precision Pathology Laboratory Services subsidiary. The net loss widened to approximately $5.3 million from $5.1 million, as the operating loss grew to approximately $3.5 million from $2.3 million, and cash fell to approximately $2.6 million at September 30, 2026, which matters to shareholders given the company's continuing losses.
Key points
- Q3 2026 revenue was approximately $1.1 million versus approximately $1.4 million in Q3 2025; nine-month CyPath Lung testing revenue rose 79% to approximately $1.1 million.
- Q3 net loss was approximately $5.3 million versus $5.1 million; loss from operations was approximately $3.5 million versus $2.3 million.
- Cash and cash equivalents were approximately $2.6 million at September 30, 2026, down from $6.4 million at December 31, 2025; a financing after quarter-end generated approximately $4.0 million in gross proceeds.
The filing
Written by AI on Nov 9, 2026, 7:05 AM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.